Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996126468> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2996126468 endingPage "S492" @default.
- W2996126468 startingPage "S492" @default.
- W2996126468 abstract "Innovative, branded doublet combination therapies are established in oncology. With more on the horizon, and triplets expected in the near future, combination therapies in oncology may challenge the sustainability of healthcare systems. New approaches to manage drug price and overall budget impact are under discussion by national HTA bodies, as well as the European Federation of Pharmaceutical Industries and Associations (EFPIA). The objective of this analysis is to understand the current and future pricing landscape for innovative, branded combination therapies. To understand national P&MA stakeholders’ intended approach to combination therapy pricing, we deep-dive into existing policies and frameworks, upcoming legislation, and position papers. Markets in focus are EU-5, and other countries piloting interesting approaches to combination therapy pricing (e.g., Switzerland, Belgium). To understand recent trends in combination pricing, we conducted a comprehensive assessment of combination therapies recently launched in multiple myeloma – including carfilzomib, daratumumab and elotuzumab in combination with lenalidomide (and dexamethasone), and bortezomib and daratumumab. The analysis indicates payers have already adopted approaches to address higher monthly cost and longer duration of treatment of combination therapies. It also identifies the key drivers of combination therapy P&MA. In many countries, these are aligned with those used to manage budget impact of high-cost oncology monotherapies. P&MA outcomes are typically the consequence of a combination of factors and are rarely driven by a single factor only. Key drivers of payer management of combination therapy pricing include regulatory label updates, availability of comparative clinical data vs. standard of care, price benchmarks at the time of the HTA assessment, and clinical outcomes. In future, payers are likely to implement further tools to manage combination therapy budget impact, such as innovative outcomes agreements, net price agreements and indication-specific pricing." @default.
- W2996126468 created "2019-12-26" @default.
- W2996126468 creator A5016405633 @default.
- W2996126468 creator A5017148065 @default.
- W2996126468 creator A5065321744 @default.
- W2996126468 date "2019-11-01" @default.
- W2996126468 modified "2023-09-30" @default.
- W2996126468 title "PCN290 IMPLEMENTATION OF COMBINATION THERAPY PRICING RULES IN ONCOLOGY: LESSONS FROM MULTIPLE MYELOMA" @default.
- W2996126468 doi "https://doi.org/10.1016/j.jval.2019.09.485" @default.
- W2996126468 hasPublicationYear "2019" @default.
- W2996126468 type Work @default.
- W2996126468 sameAs 2996126468 @default.
- W2996126468 citedByCount "0" @default.
- W2996126468 crossrefType "journal-article" @default.
- W2996126468 hasAuthorship W2996126468A5016405633 @default.
- W2996126468 hasAuthorship W2996126468A5017148065 @default.
- W2996126468 hasAuthorship W2996126468A5065321744 @default.
- W2996126468 hasBestOaLocation W29961264681 @default.
- W2996126468 hasConcept C120060458 @default.
- W2996126468 hasConcept C126322002 @default.
- W2996126468 hasConcept C143998085 @default.
- W2996126468 hasConcept C144133560 @default.
- W2996126468 hasConcept C160735492 @default.
- W2996126468 hasConcept C162324750 @default.
- W2996126468 hasConcept C166957645 @default.
- W2996126468 hasConcept C2776063141 @default.
- W2996126468 hasConcept C2776364478 @default.
- W2996126468 hasConcept C2776999253 @default.
- W2996126468 hasConcept C2777478702 @default.
- W2996126468 hasConcept C2779703844 @default.
- W2996126468 hasConcept C2780108899 @default.
- W2996126468 hasConcept C2781119759 @default.
- W2996126468 hasConcept C50522688 @default.
- W2996126468 hasConcept C71924100 @default.
- W2996126468 hasConcept C95457728 @default.
- W2996126468 hasConceptScore W2996126468C120060458 @default.
- W2996126468 hasConceptScore W2996126468C126322002 @default.
- W2996126468 hasConceptScore W2996126468C143998085 @default.
- W2996126468 hasConceptScore W2996126468C144133560 @default.
- W2996126468 hasConceptScore W2996126468C160735492 @default.
- W2996126468 hasConceptScore W2996126468C162324750 @default.
- W2996126468 hasConceptScore W2996126468C166957645 @default.
- W2996126468 hasConceptScore W2996126468C2776063141 @default.
- W2996126468 hasConceptScore W2996126468C2776364478 @default.
- W2996126468 hasConceptScore W2996126468C2776999253 @default.
- W2996126468 hasConceptScore W2996126468C2777478702 @default.
- W2996126468 hasConceptScore W2996126468C2779703844 @default.
- W2996126468 hasConceptScore W2996126468C2780108899 @default.
- W2996126468 hasConceptScore W2996126468C2781119759 @default.
- W2996126468 hasConceptScore W2996126468C50522688 @default.
- W2996126468 hasConceptScore W2996126468C71924100 @default.
- W2996126468 hasConceptScore W2996126468C95457728 @default.
- W2996126468 hasLocation W29961264681 @default.
- W2996126468 hasOpenAccess W2996126468 @default.
- W2996126468 hasPrimaryLocation W29961264681 @default.
- W2996126468 hasRelatedWork W2016202982 @default.
- W2996126468 hasRelatedWork W2478188943 @default.
- W2996126468 hasRelatedWork W2588087999 @default.
- W2996126468 hasRelatedWork W2612089043 @default.
- W2996126468 hasRelatedWork W2731606591 @default.
- W2996126468 hasRelatedWork W2783534173 @default.
- W2996126468 hasRelatedWork W2955769405 @default.
- W2996126468 hasRelatedWork W3114717300 @default.
- W2996126468 hasRelatedWork W3167371147 @default.
- W2996126468 hasRelatedWork W4307048931 @default.
- W2996126468 hasVolume "22" @default.
- W2996126468 isParatext "false" @default.
- W2996126468 isRetracted "false" @default.
- W2996126468 magId "2996126468" @default.
- W2996126468 workType "article" @default.